Skip to Content

Funding Opportunities

Current Funding Opportunities RSS

  • New Funding Opportunity Announcements (FOAs): Reissuance of Clinical Proteomic Tumor Analysis Consortium (CPTAC)

    • Release Date: November 02, 2015
    • Application Receipt Date: RFA-CA-15-021 and RFA-CA-15-023: January 27, 2016 at  5:00 PM local time of applicant organization.        RFA-CA-15-022: May 11, 2016 at  5:00 PM local time of applicant organization (see NOT-CA-16-004)

    The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the reissuance of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) program.  The program intends to leverage recent advancements in cancer proteomics and genomics and accelerate research in these areas by disseminating research resources for the scientific community.

    CPTAC will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes. In addition, the potential of proteomic and proteo-genomic approaches will be explored in translational research focused on clinically-relevant problems, such as the ability to predict which treatments are likely to be effective against a specific patient's tumor.

    The Funding Opportunity Announcements are:

    • Proteome Characterization Centers (PCCs, to be supported under RFA-CA-15-021) that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens, cultured cells, and animal cancer models) will be provided by the NCI.
      - http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-021.html
    • Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-15-022) that will apply state-of-the-art proteomic and proteo-genomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a specific patient's tumor.
      - http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-022.html
    • Proteogenomic Data Analysis Centers (PGDAC, to be supported under RFA-CA-15-023) that will conduct integrative analyses of data across the entire proteomes and genomes of cancer types of focus to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level.
      - http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-023.html

    These FOAs are open to all qualified applicants regardless of whether or not they participated in the previous issuance of the CPTAC program.

    Supporting Documents:

    Biospecimens

    Genomics

    NCI-Sponsored Clinical Trials

    Pre-Application Webinars

  • New Funding Opportunity: Tissue Purchase Order Acquisitions

    • Release Date: July 30, 2015
    • Application Receipt Date: Quotes accepted in two week intervals between August 13, 2015 at 3:00 pm Eastern and December 17, 2015 at 3:00 pm Eastern
    • Expiration Date: December 17, 2015 at 3:00 pm Eastern

    The National Cancer Institute (NCI) is expanding its basic and translational research programs that rely heavily on sufficient availability of high quality, well annotated biospecimens suitable for use in genomic and proteomic studies. The NCI’s overarching goal with such programs is to improve the ability to diagnose, treat, and prevent cancer.

    A goal of the next phase of NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is to leverage the investments in cancer genomics and achievements in cancer proteomics and apply it to additional cancer types where questions remain unanswered on the complexity between the proteome and the genome in cancer. A component of this goal is the acquisition of high‐quality, clinically annotated, primary, and untreated tumor specimens from patients with specific cancer types.

    The purpose of this notice is to notify the community that the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is seeking Tissue Source Sites (TSS) that will prospectively collect primary, human tumors according to a SOP-driven protocol optimized for proteomics. Complete cases will consist of tumor, blood, and, where possible, non-malignant tissue.

    To Learn More:

    If you are interested in learning more about this new purchase order opportunity, please visit the following websites or contact:

  • Biospecimen Core Resource to Provide Biospecimen Processing Services

    Source: Office of Cancer Clinical Proteomics Research

    • Release Date: July 02, 2015
    • Application Receipt Date: August 3, 2015 at 2pm EST

    The purpose of this notice is to notify the community that the National Cancer Institute's (NCI’s) Office of Cancer Clinical Proteomics Research (OCCPR) is seeking sources to establish a Biospecimen Core Resource (BCR), capable of receiving, qualifying, processing, and distributing annotated biospecimens.

    A goal of the next phase of NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is to improve our understanding of cancer biology by extending CPTAC’s scientific approach to additional cancer types where unanswered questions remain on their proteogenomic complexity. A component of this goal is the acquisition of high‐quality, clinically annotated, primary, and untreated tumor specimens from patients with specific cancer types. Tissue Source Sites (TSS) will prospectively collect primary, human tumors according to a SOP-driven protocol optimized for proteomics. Complete cases will consist of tumor, blood, and, where possible, non-malignant tissue.

    To Learn More:
    If you are interested in learning more about this new sub contract opportunity (Solicitation N02CO57019-02), please visit the following website or contact:

    https://www.fbo.gov/spg/HHS/NIH/FCRF2/N02CO57019-02/listing.html
    Mandie White, NCI Office of Acquisitions, at whitems@mail.nih.gov

    Background
    The Biospecimen Core Resource (BCR) serves as a biospecimen processing center as outlined in the Statement of Work (SOW) for the Clinical Proteomic Tumor Analysis Consortium (CPTAC). CPTAC is a collaborative effort led by the National Cancer Institute to accelerate our understanding of the molecular basis of cancer through the application of proteome analysis technologies, in order to better understand the proteogenomic complexity of cancer not fully elucidated through genomics.

View All »

Past Funding Opportunities RSS

View All »

Launch Antibody Portal »

The Antibody Portal serves as a public resource of well-characterized monoclonal antibodies made available by the NCI for the scientific community.

CPTAC Data Portal

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) Data Portal provides a platform for researchers to search, download, and analyze data sets generated by CPTAC.